Cooler Jobs, Hotter Trades: What A Sub‑100K Payroll Print Can Mean For Your Risk Book-( $LLY $MODD $SMWB $TSM )

Wall Street is tiptoeing into summer with inflation still in the doghouse, jobs growth cooling just enough to keep the Fed interesting, and a trio of stock-specific storylines reminding investors that stock-picking still matters in an index world.

---

Key Takeaways For Investors

• The Fed remains rhetorically welded to a 2% inflation target, keeping “higher for longer” very much alive even as growth cools.
• Private payroll gains are slowing, which supports the case for rate cuts later this year but also underscores a late-cycle feel.
• Select growth names in semis, specialty diabetes tech, and digital intelligence platforms are still winning budget share and analyst mindshare, offering pockets of upside in a choppy tape.

---

The Fed’s 2% Line In The Sand

The Fed’s Kevin Warsh has effectively reminded markets that 2% inflation is not a polite suggestion but the central bank’s institutional hill to die on. His message: the Fed will not be “comfortable” with inflation north of 2%, even if the labor market softens and political pressure to ease mounts.

For investors, that implies the bar for rapid, aggressive rate cuts remains high, and the Committee is more likely to trade a bit more unemployment for credibility than the other way around. The market’s favorite fantasy—persistent growth, easing inflation, and quick cuts—still exists, but Warsh’s comments are a reminder that the Fed’s reaction function is anchored in price stability first and asset prices a distant second.

---

Jobs: Cooling, Not Cracking

Fresh private payroll data showed that employers added fewer jobs than expected in June, clocking in at under six figures and signaling that the labor market is moving from “red‑hot” to merely “warm.” It is not a recession print, but it does take a little shine off the “no‑landing” narrative that had crept into risk assets earlier this year.

For the Fed, a softer print offers political and analytical cover to ease later in the year if inflation continues to trend toward target. For investors, it bolsters the “carry and quality” regime: higher front‑end yields remain attractive, but so do large‑cap compounders with pricing power who can navigate a slower, but not collapsing, demand backdrop.

---

Semis Still Steal The Macro Show: TSMC And Lilly

Even on a data-heavy day, equity leadership is still being written in 7‑nanometer script. Taiwan Semiconductor Manufacturing Co. Ltd. (TSM) continued to attract positive analyst attention, with at least one major firm upgrading the stock and highlighting the company’s central role in the AI and high‑performance compute build‑out.

At the same time, Eli Lilly and Co. (LLY) remains a bellwether for the “health‑span” trade, with its obesity and diabetes franchises anchoring long‑duration growth expectations and drawing renewed buy‑side conviction. The pairing of TSM and LLY on upgrade radars underscores a durable theme: markets continue to reward platforms that sit at the intersection of structural demand (AI infrastructure and metabolic health) and genuine pricing power.

---

Modular Medical: A Small‑Cap Shot Of Insulin Innovation

Modular Medical, Inc. (NASDAQ:MODD), a leader in innovative, patient-centric insulin delivery technology, today announced submission to the U.S. Food & Drug Administration (FDA) of a series of software enhancements to its PivotTM insulin delivery system, providing users with more customization options and user-interface (UI) improvements, as well as other software upgrades.

“This submission is the first of a series of further improvements and upgrades planned for the Pivot platform, now that our core form factor has been cleared by the FDA and is in the market. I want to congratulate our whole team for getting this submission in so quickly after the initial Pivot clearance,” said Jeb Besser, Chief Executive Officer of Modular Medical. “We look forward to getting feedback from the FDA in the coming weeks.”

For more information on the Pivot system, visit the dedicated site PivotPump.com.

---

Similarweb: Data As A Line Item, Not A Nice‑To‑Have

Digital intelligence provider Similarweb Ltd. (SMWB) secured a multi‑year, multi‑seven‑figure agreement with a “leading multinational tech company,” an announcement that reads like a quiet but important vote of confidence in the company’s data and platform. The fact that a large technology customer is willing to sign up for a multi‑year budget commitment reinforces the idea that third‑party digital analytics are becoming infrastructure, not discretionary spend.[

For investors, the deal checks several boxes at once: validation of SMWB’s enterprise value proposition, improved revenue visibility, and leverage to secular growth in data‑driven decision‑making across marketing, product, and strategy teams. In a macro tape still fretting about IT budgets, landing a multi‑seven‑figure subscription is a helpful rebuttal to the “every SaaS tool is negotiable” narrative.

---

How To Position Now: Quality Growth, Select Small‑Cap Optionality

The current setup—Fed still hawkish on inflation optics, labor cooling but not cracking, and alpha concentrated in genuine platforms—argues for a barbell.

• On one side, large‑cap quality such as Taiwan Semiconductor (TSM) and Eli Lilly (LLY), which combine secular growth with balance‑sheet strength.
• On the other, selectively under‑followed innovators like Modular Medical (MODD) and execution‑sensitive digital platforms like Similarweb (SMWB), where idiosyncratic catalysts can matter more than the next dot on the Fed’s SEP.

In between, investors can still harvest attractive yields in front‑end fixed income while using equity exposure to express views on AI infrastructure, metabolic health, and data monetization rather than on the precise timing of the next rate cut. As Kevin Warsh might put it, the Fed is not in the business of optimizing your Sharpe ratio—so you may as well own businesses that can do a little of that for you.

The Sources

1. Kevin Warsh / Fed on inflation staying above 2% – Yahoo Finance Policy & Economy article.
https://finance.yahoo.com/economy/policy/article/kevin-warsh-fed-will-not-be-comfortable-with-inflation-above-2-183000837.html

2. Modular Medical, Inc. (MODD) announcesl FDA submission – Yahoo Finance Healthcare article.https://finance.yahoo.com/healthcare/articles/modular-medical-announces-fda-submission-115600373.html

3. Similarweb Ltd. (SMWB) secures multi–seven‑figure deal – Yahoo Finance Markets / Stocks article https://finance.yahoo.com/markets/stocks/articles/similarweb-secures-multi-seven-figure-120000712.html

4.Private employers added fewer jobs than expected in June – Yahoo Finance Economy article. https://finance.yahoo.com/economy/article/private-employers-added-98000-jobs-in-june-fewer-than-expected-122106116.html

5.Taiwan Semiconductor Manufacturing Co. (TSM) and Eli Lilly (LLY) analyst actions – Yahoo Finance Markets / Stocks article.https://finance.yahoo.com/markets/stocks/articles/taiwan-semiconductor-upgraded-eli-lilly-192544131.html